Journal ArticleOPEN ACCESS

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy

Clinical Case Reports (2020) 8(9) 1678-1681
DOI: 10.1002/ccr3.2918
7Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The T-cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T-cell therapy.

Author supplied keywords

Cite

CITATION STYLE

APA

Tambaro, F. P., Khazal, S., Nunez, C., Ragoonanan, D., Tewari, P., Petropoulos, D., … Mahadeo, K. M. (2020). Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clinical Case Reports, 8(9), 1678–1681. https://doi.org/10.1002/ccr3.2918

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free